tirzepatide and type 2 diabetes Tirzepatide: A novel cardiovascular protective agent in mellitus obesity Tirzepatide monotherapy in Chinese patients
Description
GLP-1 receptor agonists reduce gallbladder motility
The two conditions share overlapping pathophysiological mechanisms, including systemic inflammation, endothelial dysfunction, and atherosclerosis [178]
doi: 10.1172/JCI25350 92 van LummelMvan VeelenPAZaldumbideAde RuAJanssenGMMoustakasAKet al
The condition is often idiopathic
Digestive and Liver Disease
